Management of arthralgias associated with aromatase inhibitor therapy

For the upfront adjuvant therapy of postmenopausal estrogen receptor–positive breast cancer, the third-generation aromatase inhibitors (ais) have shown a more favourable overall risk–benefit profile than has tamoxifen. Benefits of the ais include less frequent gynecologic, cerebrovascular, and throm...

Descripción completa

Detalles Bibliográficos
Autor principal: Thorne, C.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2007
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2140182/
https://www.ncbi.nlm.nih.gov/pubmed/18087604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2140182/
https://www.ncbi.nlm.nih.gov/pubmed/18087604

Ejemplares similares